Irinotecan Kabi 20 mg/ml concentrate for solution for infusion
Country: Bulgarija
Lingwa: Bulgaru
Sors: Изпълнителна агенция по лекарствата
Fuljett ta 'informazzjoni
(PIL)
26-09-2022
Karatteristiċi tal-prodott
(SPC)
26-09-2022
Ingredjent attiv:
Иринотекан
Disponibbli minn:
Fresenius Kabi Oncology Plc.
Kodiċi ATC:
L01XX19
INN (Isem Internazzjonali):
Irinotecan
Dożaġġ:
20 mg/ml concentrate for solution for infusion
Sommarju tal-prodott:
Irinotecan Kabi, 20 mg/ml concentrate for solution for infusion - 2 ml x 1;2 ml x 5; 5 ml x 1; 5 ml x 5
Data ta 'l-awtorizzazzjoni:
2013-12-18
